Have a feature idea you'd love to see implemented?
Let us know!
GALT Galectin Therapeutics Inc
Price (delayed)
$2.72
Market cap
$170.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.73
Enterprise value
$248.21M
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin (formerly known as GR-MD-02) is a
Highlights
Galectin Therapeutics's EPS has increased by 8% QoQ and by 3.9% YoY
The company's net income rose by 6% QoQ
GALT's equity has dropped by 79% year-on-year and by 12% since the previous quarter
The debt has soared by 71% YoY and by 12% from the previous quarter
Key stats
What are the main financial stats of GALT
Market
Valuations
Earnings
Shares outstanding
62.76M
Market cap
$170.71M
Enterprise value
$248.21M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$40.42M
EBITDA
-$40.38M
Free cash flow
-$33.68M
Per share
Balance sheet
Liquidity
EPS
-$0.73
Free cash flow per share
-$0.54
Book value per share
-$1.51
Revenue per share
$0
TBVPS
$0.47
Total assets
$28.97M
Total liabilities
$121.45M
Debt
$104.55M
Equity
-$94.2M
Working capital
$3.41M
Debt to equity
-1.11
Current ratio
1.13
Quick ratio
1.07
Net debt/EBITDA
-1.92
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-163.4%
Return on equity
N/A
Return on invested capital
-55.2%
Return on capital employed
-1,088.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GALT stock price
How has the Galectin Therapeutics stock price performed over time
Intraday
-3.37%
1 week
-1.09%
1 month
3.42%
1 year
39.49%
YTD
63.86%
QTD
-1.09%
Financial performance
How have Galectin Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$39.57M
Net income
-$45.08M
Gross margin
N/A
Net margin
N/A
The company's net income rose by 6% QoQ
Growth
What is Galectin Therapeutics's growth rate over time
Valuation
What is Galectin Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Galectin Therapeutics's EPS has increased by 8% QoQ and by 3.9% YoY
GALT's equity has dropped by 79% year-on-year and by 12% since the previous quarter
Efficiency
How efficient is Galectin Therapeutics business performance
GALT's ROIC is up by 44% YoY and by 17% QoQ
The ROA has grown by 25% YoY and by 12% from the previous quarter
Dividends
What is GALT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GALT.
Financial health
How did Galectin Therapeutics financials performed over time
Galectin Therapeutics's total assets is 76% less than its total liabilities
The total liabilities has soared by 66% YoY and by 11% from the previous quarter
Galectin Therapeutics's quick ratio has decreased by 45% YoY and by 39% QoQ
GALT's equity has dropped by 79% year-on-year and by 12% since the previous quarter
The debt has soared by 71% YoY and by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.